IntelGenx Technologies Corp. (IGXT)
OTCMKTS: IGXT · Delayed Price · USD
0.167
0.00 (0.00%)
May 16, 2024, 4:00 PM EDT - Market closed
IntelGenx Technologies Revenue
IntelGenx Technologies had revenue of $1.05M in the twelve months ending March 31, 2024, with 20.11% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $174.00K with 7.41% year-over-year growth. In the year 2023, IntelGenx Technologies had annual revenue of $1.04M with 9.37% growth.
Revenue (ttm)
$1.05M
Revenue Growth
+20.11%
P/S Ratio
27.75
Revenue / Employee
$21,896
Employees
48
Market Cap
29.17M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1.04M | 89.00K | 9.37% |
Dec 31, 2022 | 950.00K | -585.00K | -38.11% |
Dec 31, 2021 | 1.54M | -9.00K | -0.58% |
Dec 31, 2020 | 1.54M | 802.00K | 108.09% |
Dec 31, 2019 | 742.00K | -1.08M | -59.32% |
Dec 31, 2018 | 1.82M | -3.37M | -64.89% |
Dec 31, 2017 | 5.20M | -25.00K | -0.48% |
Dec 31, 2016 | 5.22M | 125.00K | 2.45% |
Dec 31, 2015 | 5.10M | 3.44M | 207.11% |
Dec 31, 2014 | 1.66M | 711.00K | 75.00% |
Dec 31, 2013 | 948.00K | -260.00K | -21.52% |
Dec 31, 2012 | 1.21M | 768.00K | 174.55% |
Dec 31, 2011 | 440.00K | -897.00K | -67.09% |
Dec 31, 2010 | 1.34M | 58.30K | 4.56% |
Dec 31, 2009 | 1.28M | 302.09K | 30.93% |
Dec 31, 2008 | 976.61K | 141.20K | 16.90% |
Dec 31, 2007 | 835.42K | 569.51K | 214.18% |
Dec 31, 2006 | 265.90K | - | - |
Dec 31, 2005 | 0 | - | - |
Dec 31, 2004 | 0 | - | - |
Dec 31, 2003 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 379.49B |
Johnson & Johnson | 81.80B |
Merck & Co. | 61.40B |
AbbVie | 54.40B |
Novartis AG | 49.92B |
AstraZeneca | 47.61B |
Thermo Fisher | 42.49B |
Abbott Laboratories | 40.33B |
IGXT News
- 21 days ago - IntelGenx Announces Initiation of the Sale and Investment Solicitation Process - GlobeNewsWire
- 5 weeks ago - IntelGenx Obtains Court-Approval of a Sale and Investment Solicitation Process - GlobeNewsWire
- 6 weeks ago - IntelGenx Initiates Restructuring Proceedings Under the CCAA to Implement a Review of its Strategic Alternatives - GlobeNewsWire
- 7 weeks ago - IntelGenx Announces Voting Results on Election of Directors - GlobeNewsWire
- 3 months ago - IntelGenx Announces First Parkinson's Disease Patients Dosed with Montelukast VersaFilm® in Phase 2 ‘MONTPARK' Clinical Trial - GlobeNewsWire
- 3 months ago - IntelGenx Updates Status of Buprenorphine Buccal Film ANDA - GlobeNewsWire
- 3 months ago - IntelGenx Reports Fourth Quarter and Full-Year 2023 Financial Results - GlobeNewsWire
- 3 months ago - IntelGenx to Report Fourth Quarter and Full Year 2023 Financial Results on March 21, 2024 – Conference Call to Follow - GlobeNewsWire